Active Biotech (BTPC) Stock Overview
A biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BTPC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0038 |
| 52 Week High | SEK 0.031 |
| 52 Week Low | SEK 0.0016 |
| Beta | 1.47 |
| 1 Month Change | 123.53% |
| 3 Month Change | -37.70% |
| 1 Year Change | -46.48% |
| 3 Year Change | -93.32% |
| 5 Year Change | -97.41% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTPC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -2.0% | -2.1% |
| 1Y | -46.5% | -12.4% | 11.4% |
Return vs Industry: BTPC underperformed the German Biotechs industry which returned -11.9% over the past year.
Return vs Market: BTPC underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| BTPC volatility | |
|---|---|
| BTPC Average Weekly Movement | 74.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BTPC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BTPC's weekly volatility has increased from 60% to 74% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 5 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center.
Active Biotech AB (publ) Fundamentals Summary
| BTPC fundamental statistics | |
|---|---|
| Market cap | €10.48m |
| Earnings (TTM) | -€3.59m |
| Revenue (TTM) | n/a |
Is BTPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTPC income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 38.50m |
| Earnings | -SEK 38.50m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BTPC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 05:39 |
| End of Day Share Price | 2026/01/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Active Biotech AB (publ) is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stefan Waldenlind | Carnegie Investment Bank AB |
| Thomas Bowers | Danske Bank |
| Robin Davison | Edison Investment Research |